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S U M M A R Y
Background: Candidemia is among the leading causes of nosocomial bloodstream infections and is
associated with signiﬁcant mortality. Several centers have published data regarding the incidence and
relative frequency of Candida spp.
Objective: We performed a systematic review to summarize and evaluate the available evidence
regarding the distribution of the relative frequency of Candida spp isolated from blood, according to
geographic region and study design, during the period 1996 to 2009.
Methods: We searched PubMed and Scopus and retrieved 81 relevant articles reporting data on the
relative frequency of Candida spp.
Results: C. albicans was the predominant species in almost all studies. The highest proportion of C.
albicanswas found in North and Central Europe and the USA. Non-albicans species were more common
in South America, Asia, and South Europe. C. glabrata was commonly isolated in the USA and North and
Central Europe; C. parapsilosis in South America, South Europe, and several parts of Asia; and C. tropicalis
in South America and Asia. The relative frequency of C. krusei was low in all regions. Signiﬁcant
differences were noted depending on study design (surveillance study, multicenter or single centre,
prospective or retrospective) and setting (hospital or intensive care unit).
Conclusions: Signiﬁcant geographic variation is evident among cases of candidemia in different parts of
the world. Local epidemiological data continue to be of major signiﬁcance.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
journa l homepage: www.e lsev ier .com/ locate / i j idIntroduction
Candidemia is the fourth most common nosocomial blood-
stream infection in the USA.1,2 The incidence of candidemia has
risen over the last two decades, in several parts of the globe and in
different settings,3,4 mostly due to an increase in the use of more
aggressive therapy practices (mainly intensive chemotherapy of
hematological malignancies, transplantation, and intensive care
unit (ICU) use, and to a lesser extent the use of immunosuppressive
agents for the treatment of autoimmune diseases and other
diseases and even life prolongation), which have created a
previously non-existent immunocompromised population.5,6 Also,
a shift in the relative frequency of each Candida spp isolated in
blood has been reported.7–15
Candidemia is associated with considerable mortality.16–18
Therefore, in patients with accumulating risk factors for candide-* Corresponding author. Tel.: +30 694 611 0000; fax: +30 210 683 9605.
E-mail address: m.falagas@aibs.gr (M.E. Falagas).
1201-9712/$36.00 – see front matter  2010 International Society for Infectious Disea
doi:10.1016/j.ijid.2010.04.006mia, in whom the probability for candidemia is high, clinicians use
empirical treatment long before laboratory results on species
identiﬁcation and antibiograms are available, when the infection is
suspected.19,20 In order to apply an effective treatment, it is
essential to have a valid, regularly updated knowledge of the
proportion of Candida spp causing candidemia.
A signiﬁcant variability in the relative frequency of candidemia
has been noticed in different regions within a given country. In
addition, signiﬁcant variability has been noticed within studies,
especially in multicenter studies enrolling patients in different
settings (e.g., ICU, hospitals, outpatients, etc.) and studies lasting
for longer periods, which have reported different distributions of
Candida spp, not only within regions but also over time. In the
current study we sought to assess the proportions in which
different Candida spp are isolated worldwide.
Methods
We performed searches in the PubMed and Scopus databases
(until January 2009) using the following keywords: ‘Candida’,ses. Published by Elsevier Ltd. All rights reserved.
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M.E. Falagas et al. / International Journal of Infectious Diseases 14 (2010) e954–e966 e955‘candidemia’, ‘Candida bloodstream infection’, ‘Candida epidemi-
ology’, ‘Candida species trends’, ‘species distribution’, ‘species
spectrum’, and ‘ICU candidemia’ and performed additional
handpicked searches in the bibliographies of the retrieved articles
and reviews. Two of the authors (NR, KZV) independently
performed the electronic search.
Studies were included in the review only if they were written in
the English language. We also excluded studies if they were
completed prior to year 1997 in order to study the epidemiology of
candidemia over the last decade. The rationale behind this choice
was two-fold: ﬁrst, to describe the epidemiology of candidemia in
recent years (and the possible changes during these years) and
second, to minimize bias associated with changes in clinical
practice through the years. In addition, several reviews have been
published describing the distribution of Candida spp among
patients with candidemia in the years prior to 1997.
For studies conducted both before and after this time point, we
either extracted the data of interest after year 1996 whenever
possible or, when data regarding each year of the study period
were not available, included the entirety of their ﬁndings if more
than half the years of the study period were after 1996. We
extracted data regarding the overall incidence of candidemia in
these settings, the total number of Candida spp isolates in the
observed candidemia cases, and the relative proportion of each
Candida spp in each study.
We grouped the collected articles in three categories: multicen-
ter or surveillance studies, cohort studies performed in hospitals,
and studies conducted in ICUs. Thiswasdone inorder to createmore
homogenous populations. Then, each of these populations was
studied according to three subcategories: their geographic distribu-
tion, the study design (prospective or retrospective), and age of the
studied population. The relative frequency of different Candida spp
bloodstream infectionswas studiedwithin each of these subgroups.
In addition, if data were available, the changes in the relative
frequency of Candida spp over time were studied.
Results
We retrieved 22 articles1,2,21–40 reporting data from multicen-
ter hospital-based or surveillance studies, 41 articles23,41–80
reporting data from hospitals, and 18 articles23,56,57,60,62,81–93
regarding studies conducted in ICUs. The extracted data from these
articles are presented in Tables 1–3 (ﬁve studies23,56,57,60,62 were
eligible for both Tables 2 and 3 since they reported data for
candidemia at the hospital and ICU level). C. albicans was the
dominant species in almost all studies included in this review.
Geographic distribution
Surveillance studies
When data from surveillance studies only were reviewed, C.
albicans predominated in the countries of North Europe and
Switzerland (>60%),was equally isolated in the remainingEuropean
countries and the USA (ranging from 45% to 58%), and was lower in
Asia and South America (approximately 40–42%). Accordingly, non-
albicans species predominated in Asia. The highest proportions of C.
glabratawere reported in studies from the USA (18.8–24%) and the
UK (22.7%) and the lowest were reported in studies from Brazil and
Kuwait (4.9% and 5.6%, respectively). C. parapsilosis was more
frequently isolated in Kuwait (30.6%), South America (20.5–21.3%),
Spain (23%), and Australia (19.9%), and the lowest proportion was
found in Switzerland (1–5%) and North Europe (4.4%). C. tropicalis
held higher proportions in South America (20.9–24.2%) and Taiwan
(22.4%), intermediate in theUSA (11–12%), and lowest inCentral and
North Europe (4%). C. krusei was not commonly isolated (ranging
from 1% to 4%), except from one study in Finland and one in France
Table 1 (Continued )
Author, year [Ref.] Study design/
observation
time period/
participating
institutions
Incidence Total
number
of blood
isolatesa
C.
albicans
C.
glabrata
C.
parapsilosis
C.
tropicalis
C.
krusei
C.
guillermondii
C.
lusitaniae
C.
famata
C.
inconspicua
C.
dubliniensis
C.
norvegensis
Other
Candida
sppb
Trends
in relative
species
proportions
France
Martin
et al., 2005 [31]
Prospective,
1998–2001, area
of Lyon (covered
by a group of
hospitals)
Ranges from 0.1 to
3.7 cases/1000
admissions
198 49.5% 12.6% 12.1% 10.1% 10.6% - 0.5% 1% - - - 3.5% The study described
an increase in the
incidence of
C. glabrata and
C. krusei
Ireland
Boo
et al., 2005
(part I) [23]
Prospective,
1996–2003, 10
hospitals (original
period 1992–2003)
For the 1999–2003
period: 0.48 cases/1000
admissions/year or
0.6–0.84 cases/
10 000 patients
174 1996–99:
79.5%,
2000–03:
58.3%
1996–99:
6.4%,
2000–03:
12.5%
1996–99:
11.5%,
2000–03:
19.8%
1996–99:
2.6%,
2000–03:
5.2%
- - - - - - - 1996–99:
0%,
2000–03:
5.2%
The study
demonstrated a
rising proportion
of C. glabrata
UK
Odds
et al., 2007 [33]
Prospective,
2005–2006, 19
tertiary hospitals
in Scotland
4.8 cases/100 000
population/year or 5.9
cases/100 000 acute
occupied beds/year
300 52% 22.7% 11.7% 2% 1% 3.3% 2% - - 3% - - The study showed
an unusually high
frequency of
C. dubliniensis
Switzerland
Marchetti
et al., 2004 [30]
Retrospective,
1997–2000, 17
university and
tertiary care
hospitals (original
period 1991–2000)
For year 2000: 0.54
cases/10 000 patient-
days or 0.36 cases/
1000 admissions
464c 65–70% 15% 1–5% 5–9% 1–2% - - - - - - 8–10% No shift to
azole-resistant
Candida spp was
observed over the
original 10-year
study period
Belgium
Swinne
et al., 2004 [37]
Prospective, 2002,
national surveillance
program (28
hospitals participating)
NA 203 55% 23.2% 12.8% 2.9% 2.5% 0.9% 0.5% - - - 0.5% - The study concluded
that the frequency
of non-albicans
species in candidemia
is increasing
(compared to older
studies)
Iceland
Asmundsdottir
et al., 2002 [22]
Prospective,
1995–1999, nationwide
study (original period
1980–1999)
4.9 cases/100 000
population/year
70 64.3% 12.9% 11.4% 5.7% - - - - - - 5.7% - The relative frequency
of Candida species in
candidemia did not
change signiﬁcantly
during the 2 halves
of the original study
period
Finland
Lyyticainen
et al., 2002 [29]
Prospective, 1999–2000,
surveillance program
(4 hospitals participating)
NA 62 62.9% 6.5% 12.9% 2.3% - - - - - - - 14.5% Candidemia from
non-albicans species
was less common
compared to other
studies
Poikonen
et al., 2003 [35]
Prospective, 1997–1999,
data from NIDR program
(original period
1995–1999)
1.8–2.2 cases/100 000
population/year
305 69.2% 8.5% 5.6% 3% 8.5% - - - - - - 5.2% The study reported
no notable shift from
C. albicans to
non-albicans species
M
.E
.
Fa
la
g
a
s
et
a
l./In
tern
a
tio
n
a
l
Jo
u
rn
a
l
o
f
In
fectio
u
s
D
isea
ses
1
4
(2
0
1
0
)
e9
5
4
–
e9
6
6
e9
5
6
Norway
Sandven
et al., 2006 [36]
Prospective, 1997–2003,
nationwide surveillance
(original study period
1991–2003)
Range 2.2–3.3 cases/
100 000 population
862 70.7% 13.4% 4.4% 6.8% 1.3% 0.2% - - - 0.5% 0.7% 0.5% The study reported
no notable shift
from C. albicans to
non-albicans species
USA
Edmond
et al., 1999 [1]
Prospective,
1995–1998, 49 hospitals
NA 934 53.2% 19.8% 9.9% 12.2% - - - - - - - 4.9% C. glabrata was the
dominant non-
albicans species
with the exception
of pediatric patients
where the main
non-albicans was
C. parapsilosis
Hajjeh
et al., 2004 [27]
Prospective,
1998–2002, 47
hospitals in 2 states
(14 in Baltimore and
33 in Connecticut)
Baltimore: 24 cases/
100 000 population/year
Connecticut: 7 cases/
100 000 population/year
1143 45% 24% 13% 12% 2% - 1% - - 0.9% - 0.2% The study showed
an increasing
frequency of
C. glabrata (consistent
with the results of
previous studies)
Wisplinghoff
et al., 2004 [2]
Prospective, 1995–2002,
SCOPE nationwide
surveillance study
NA 1890 53.8% 18.8% 11.4% 11.2% 2.4% - - - - - - 2.4% The relative
frequencies of
C. albicans and
C. parapsilosis have
increased and those
of C. tropicalis and
C. glabrata have
decreased
Dieckema
et al., 2002 [25]
Prospective, 1998–2001,
16 hospitals in the
state of Iowa
6 cases/ 100 000
population/year
254 58% 20% 7% 11% 2% - 0.8% 0.4% - - - 0.8% The study showed
an increase in the
relative frequency
of C. glabrata along
with increasing age
South America
Godoy
et al., 2003 [26]
Prospective, 1999–2003,
5 tertiary care hospitals
from 4 countries
NA 103
episodes of
candidemia
42% 7.7% 21.3% 24.2% - 2.9% 1.9% - - - - The study depicts
the high prevalence
of C. tropicalis
Brazil
Colombo
et al., 2006 [24]
Prospective, 2003–2004,
11 tertiary care hospitals
2.49 cases/1000
admissions or
0.37 cases/1000
patient-days
711 40.9% 4.9% 20.5% 20.9% 1.1% 2.4% - - - - - 6.2% The study showed
that C. tropicalis
and C. parapsilosis
are the dominant
candidemia
pathogens
Japan
Takakura
et al., 2004 [38]
Prospective, 2001–2002,
nationwide surveillance
(105 institutions
participating)
NA 535 40.7% 17.9% 23% 11.6% 2.4% 1.3% 0.6% 0.7% - 0.2% - 1.5% The study showed
that the relative
frequency of
C. albicans tends to
decrease with age
Taiwan
Kung
et al., 2007 [28]
Prospective, 1995–2005,
community-onset
candidemia
NA 56
episodes of
candidemia
39.7% 17.2% 15.5% 22.4% 1.7% 1.7% - 1.7% - - - - The study showed
a high frequency
of C. parapsilosis
possibly due to
its abundance in
the community
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Table 1 (Continued )
Author, year [Ref.] Study design/
observation
time period/
participating
institutions
Incidence Total
number
of blood
isolatesa
C.
albicans
C.
glabrata
C.
parapsilosis
C.
tropicalis
C.
krusei
C.
guillermondii
C.
lusitaniae
C.
famata
C.
inconspicua
C.
dubliniensis
C.
norvegensis
Other
Candida
sppb
Trends
in relative
species
proportions
Kuwait
Mokkadas
et al., 2007 [32]
Prospective, 1996–2005,
tertiary hospitals
in Kuwait
NA 607 39.5% 5.6% 30.6% 12.4% 1.6% - - - - - - 10.2% The study showed
a high frequency
of C. parapsilosis
consistent with
previous studies
Australia
Chen
et al., 2006 [90]
Prospective surveillance,
2001–2004
1.81 cases/
100 000 population
1095 47.3% 15.4% 19.9% 5.1% 4.3% - - – - 1.9% - 4.0%
Ref., reference; NA, relevant data were not available; ECMM, European Confederation on Medical Mycology; NIDR, National Infectious Disease Register; SCOPE, Surveillance and Control of Pathogens of Epidemiological Importance.
a Refers to the total number of Candida isolates from blood (or to the total number of candidemia episodes where the former was not available from the original study).
b Includes Candida spp not depicted in the Table and Candida spp not identiﬁed to species level.
c Approximate numbers calculated from ﬁgure.
Table 2
Relative frequency of Candida spp in candidemia in hospital-based studies
Author, year [Ref.] Study design/
observation time
period/ participating
institutions
Total
number of
blood isolatesa
C.
albicans
C.
glabrata
C.
parapsilosis
C.
tropicalis
C.
krusei
C.
guillermondii
C.
lusitaniae
C.
famata
C.
inconspicua
C.
dubliniensis
C.
norvegensis
Other
Candida
sppb
Incidence
Europe
Portugal
Costa-de-Oliveira
et al., 2008 [56]
Prospective, 2004,
university hospital
95 43% 9% 32% 16% - - - - - - - - 2–2.7 cases of
fungemia/1000
admissions
Greece
Samonis et al.,
2008 [68]
Retrospective,
2001–2006, tertiary
care hospital
140
episodes of
candidemia
46% 13.6% 14.3% 21.4% 2.1% 1.4% 1.4% - - - - - NA
Italy
Luzzati et al.,
2005 [63]
Retrospective,
1998–2001, tertiary
care hospital (original
period 1992–2001)
106 48.1% 6.6% 17.9% 4.7% 0.8% 4.7% 1.9% 1.9% - - 0.9% 11.3% NA
Bedini et al.,
2006 [47]
Prospective, 2000–2003,
tertiary care hospital
94 40.4% 12.8% 22.3% 15.9% 3.2% 2.1% 2.1% - - - - 1% 0.9 cases/10 000
patient-days
Caggiano et al.,
2008 [50]
Prospective, 1998–2004,
university hospital
155
episodes of
candidemia
45.8% 4.5% 35.5% 4.5% 3.2% 3.2% - 0.6% - - - 2.6% 2–5.1 cases/1000
admissions
Ireland
McMullan et al.,
2002 [64]
Retrospective,
1996–2000, university
hospital (original period
1984–2000)
75 53% 27% 11% 6.4% - - - - - - - 2.6% NA
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Boo et al., 2005
(part II) [23]
Retrospective,
1999–2003, tertiary
care hospital
66 50% 18.2% 21.2% 6.1% - - - 1.5% - 1.5% - 1.5% 0.48 cases/1000
admissions/year
Metwally et al.,
2007 [66]
Retrospective,
2001–2006, university
hospital
151 63.5% 17.2% 12% 3.3% - 2.6% - 0.7% - 0.7% - - NA
UK
Schelenz
et al., 2003 [71]
Retrospective,
1995–2001, teaching
hospital
129 64.3% 20% 5.4% 8.5% 0.8% - 0.8% - - - - - 0.3 cases/1000
admissions
Aliyu et al.,
2006 [43]
Retrospective,
2001–2004, tertiary
care hospital
95 46.3% 24.2% 10.5% 5.3% 4.2% 2.1% 2.1% - - - - 5.2% NA
Switzerland
Garbino
et al., 2002 [58]
Retrospective,
1997–2000, university
hospital (original
period 1989–2000)
75 61.3% 21.3% 4% 4% 5.3% 2.6% - - - - - 1.3% 0.2–0.31 cases/
10 000 patient-days
Belgium
Lagrou
et al., 2007 [61]
Retrospective,
2001–2005, university
hospital
420 59.8% 22.6% 9.8% 4.5% 1.2% 0.2% 1.2% - - 0.2% - 0.2% During the study
period: 1.68!1.3
cases of fungemia/
10 000 patient-days
(a similar rate for
candidemia is reported)
Netherlands
Verduyn Lunel
et al., 2006 [73]
Retrospective,
1996–2001, 5 university
hospitals
357 57.1% 19.6% 9% 7.3% 3.4% 0.3% 1.7% - - 0.3% - 1.4% 0.82 cases/
10 000 patient-days
Sweden
Klingspor
et al., 2004 [60]
Prospective,
1998–1999, 6 hospitals
196 66.8% 15.8% 7.1% 2% 1% 0.5% 2.5% - - - 0.5% 1.5% 0.32 cases/1000
patients hospitalized
>1 day
Hungary
Doczi et al.,
2002 [56]
Retrospective,
1997–2000, university
hospital (original period
1996–2000)
120 81.7% 2.5% 4.2% 3.3% 5.8% - - - - - - 0.8% NA
North America
USA
Baran et al.,
2001 [45]
Retrospective,
1994–1997, tertiary care
hospital (original period
also: 1986–1989)
98 50% 7% 24% 16% 2% - - - - - - 1% During the study
period: 0.09!0.06
cases/1000 admissions
Abelson et al.,
2005 [42]
Retrospective, 1997–2001,
tertiary care pediatric
hospital (original period
1991–2001)
59
episodes of
candidemia
52.9% 2.2% 27.5% 11.8% 3.4% - 2.2% - - - - - On average: 6 cases of
fungemia/1000
inpatients
Morrell et al.,
2005 [91]
Retrospective, 2001–2004,
teaching hospital
157 53.5% 12.7% 15.9% 12.7% 1.3% - - - - - - - NA
South America
Brazil
Antunes et al.,
2004 [43]
Retrospective,
2002–2003, tertiary care
hospital
120 48.3% 3.3% 25.8% 13.3% 1.7% 1.7% 0.8% 1.7% - 0.8% - 2.5% NA
Aquino et al.,
2005 [44]
Retrospective,
1998–2004, tertiary
care hospital
131 45% 6.9% 24.4% 15.3% 4.6% 0.8% 0.8% - - - - 2.3% NA
Barberino et al.,
2006 [46]
Retrospective,
1997–2005, 3 tertiary
hospitals
25 56% 4% 4% 16% 0% 4% - 4% - - - 12% NA
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Table 2 (Continued )
Author, year [Ref.] Study design/
observation time
period/ participating
institutions
Total
number of
blood isolatesa
C.
albicans
C.
glabrata
C.
parapsilosis
C.
tropicalis
C.
krusei
C.
guillermondii
C.
lusitaniae
C.
famata
C.
inconspicua
C.
dubliniensis
C.
norvegensis
Other
Candida
sppb
Incidence
Medrano et al.,
2006 [65]
Prospective,
2000–2002, tertiary
care hospital
50 28% 4% 36% 16% - 12% - - - - - 4% NA
Colombo et al.,
2007 [54]
Prospective,
2002–2003, 4 tertiary
hospitals
282 38% 3% 23% 17% 1% 6% 1% - - - - 7% 1.66 cases/1000
admissions
Chang et al.,
2008 [52]
Retrospective,
1998–2006, tertiary care
hospital
96 45.8% 5.2% 34.4% 14.6% - - - - - - - - NA
Franka et al.,
2008 [40]
Retrospective,
2001–2004, tertiary
care hospital
100 59% 7% 9% 15% 2% 2% 1% - - - - 5% 1.27 cases/1000
admissions
Argentina
Giusiano et al.,
2004 [60]
Prospective,
1999–2002, pediatric
hospital
46 34.8% 10.9% 28.3% 15% - 2.2% 2.2% 4.3% - - - 2.1% NA
Asia
Turkey
Yapar et al.,
2006 [78]
Retrospective,
2000–2003, tertiary
care hospital
104 57.7% 3.8% 12.5% 20.2% 1% 3.8% - - - - - 1% 0.56 cases/1000
admissions
Celebi et al.,
2008 [52]
Prospective,
1997–2005, tertiary
care hospital
102 39.2% 6.9% 21.6% 15.7% 4.9% - 3.9% - - - - 7.85% 5.1 cases/1000
admissions
Saudi Arabia
Bukharie,
2002 [49]
Retrospective,
1995–2000, teaching
hospital
32 19% 3% 44% 8% 6% 3% - - - - - - NA
Osoba et al.,
2003 (abstract
only available) [67]
Prospective,
1998–2002, hospital
82 46% 4.8% 10.8% 10.8% 6% - - - - - - 13.2% NA
United Arab Emirates
Ellis et al.,
2003 (abstract
only available)
[57]
Retrospective,
1995–2001, hospital
60
episodes of
candidemia
45% 5% 5% 15% - - 1% 2% - - - 2% 0.77 cases/1000
admissions
Israel
Samra et al.,
2005 [69]
Prospective,
2003–2004, tertiary
care hospital
142 44.3% 9.8% 20.4% 24.6% 0.7% - - - - - - - NA
Weinberger
et al., 2005 [76]
Prospective,
1995–2000, 3 tertiary
care hospitals
272c 55% 10% 16% 16% 2% 0.4% 0.4% - - - 0.4% 1% NA
India
Verma et al.,
2003 [75]
Prospective,
2000–2001, tertiary
care hospital
21 33% 9.5% 9.5% 33% 4.8% 4.8% 4.8% - - - - - 1.61 cases/1000
admissions
Capoor et al.,
2005 [50]
Prospective,
2003–2004, tertiary
care hospital
30 17% - 23% 60% - - - - - - - - NA
Xess et al.,
2007 [78]
Retrospective,
2005, tertiary care
hospital
275 21.5% 17.5% 20% 35.3% 3.3% 1% - - - - - 1.5% NA
Taiwan
Cheng et al.,
2006 [54]
Retrospective,
1996–1999, tertiary
hospital
383 55.6% 5.2% 17.5% 16.5% - 2.3% - 0.8% - - - 2.3% NA
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Wang et al.,
2004 [75]
Prospective,
2002, university
hospital
230 48.3% 13% 13.9% 21.7% 1.3% 1.3% - - - - - - NA
Tsai et al.,
2008 [72]
Retrospective,
2003–2005, tertiary
care hospital
179
episodes of
candidemia
63.7% 11.7% 10.6% 12.2% - - - - - - - 1.7% NA
Singapore
Tan et al.,
2008 [71]
Retrospective,
2004–2006, 3
hospitals
279 37.3% 16.1% 14.3% 26.9% 0.7% 0.4% - - - 2.9% - 1.5% NA
Korea
Lee et al.,
2007 [62]
Prospective,
2004–2005, 8 university
hospitals
148 49% 11% 22% 14% 1% 2% - - - - - - NA
Ref., reference; NA, relevant data were not available.
a Refers to the total number of Candida isolates from blood (or to the total number of candidemia episodes where the former was not available).
b Includes Candida spp not depicted in the Table and Candida spp not identiﬁed to species level.
c Number of patients with candidemia.
Table 3
Relative frequency of Candida spp in candidemia in ICU patients
Author, year, country [Ref.] Study design/
observation
time period/
participating
institutions
Total
number
of blood
isolatesa
C.
albicans
C.
glabrata
C.
parapsilosis
C.
tropicalis
C.
krusei
C.
guillermondii
C. l
usitaniae
C.
famata
C.
inconspicua
C.
dubliniensis
C.
norvegensis
Other
Candida
sppb
Incidence
Trubenova et al., 2001,
Slovakia [90]
NA, PICU 42 41% 0% 48% 7% 2% - - - - - - 2% NA
Doczi et al., 2002,
Hungary [56]
Retrospective,
1996–2000, adult
ICUs and PICUs
60 88.3% 3.3% 3.3% 3.3% - - - - - - - 1.7% NA
Rani et al., 2002,
India [84]
NA, 2000, NICU 50 4% - - 92% - - - - - - - 4% NA
Roilides et al., 2004,
Greece [86]
Prospective, 2004,
NICU
59
episodes of
candidemia
65% 2% 16% 7% - 3% 5% - - - - 2% NA
Boo, et al., 2005 Ireland
(part II) [23]
Retrospective,
1999–2003, ICU
33 45.5% 24.2% 18.2% 6.1% - - - 3% - 3% - - Range: 21.55–34.04
cases/1000
admissions or
11.19–17.3 cases
/10 000 patient-
days
Shetty et al., USA,
2005 [87]
Prospective,
1998–2000, 7 PICUs
35 54.3% 14.3% 25.7% - - - - - - - - 5.7% NA
Giusiano et al., 2005,
Argentina [59]
NA, 1999–2002, PICU 46 34.8% 10.9% 28.3% 15.2% - 2.2% 2.2% 4.3% - - - 2.2% NA
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Author, year, country [Ref.] Study design/
observation
time period/
participating
institutions
Total
number
of blood
isolatesa
C.
albicans
C.
glabrata
C.
parapsilosis
C.
tropicalis
C.
krusei
C.
guillermondii
C. l
usitaniae
C.
famata
C.
inconspicua
C.
dubliniensis
C.
norvegensis
Other
Candida
sppb
Incidence
Rodriguez et al., 2006,
Spain [85]
Prospective,
2002–2003, 5 NICUs
24
episodes of
candidemia
29% 4% 67% - - - - - - - - - 32.6 cases/100 000
live-births or 1.1
cases/100 ICU
discharges
Comert et al., 2007,
Turkey [83]
Prospective,
2002–2005, ICU
23 39.1% 13% 21.7% - 8.7% 17.4% - - - - - - NA
Bassetti et al., 2006,
Italy [79]
Retrospective,
1999–2003, medical
and surgical ICU
182 40% 15% 23% 9% 13% - - - - - 2.22 cases/10 000 patients/year
Lagrou et al., 2007,
Belgium [61]
Retrospective,
2001–2005, NICUs,
hematology, ICUs
and emergency units
420 59.8% 22.6% 9.8% 4.5% 1.2% 0.2% 1.2% - - 0.2% - 0.2% NA
Costa-de-Oliveira
et al., 2007,
Portugal [55]
Prospective, 2004, ICU 97 42.3% 9.3% 30.9% 15.5% - 1% 1% - - - - NA
Dimopoulos
et al., 2007,
Greece [84]
Prospective,
2001–2005, mixed
medical– surgical
ICU
56 64.3% 14.3% 5.4% 10.7% 1.8% - 1.8% - - 1.8% - - NA
Bougnoux
et al., 2008,
France [80]
Prospective,
2001–2002,
medical, surgical,
hematological and
burn ICUs
57 54.2% 17% 13.5% 8.5% 3.5% - - - - - - 3.4% 6.7 cases/1000
admissions or 0.69
cases/1000 patient-
days
Fridkin et al.,
2006, USA [85]
Prospective,
1995–2004, 128
NICUs (participants
of NNISS)
1997
episodes of
candidemia
57.9% 2% 33.7% 3.8% 0.2% - 2.3% - - - - - 1.48 cases/1000
patient-days
Playford et al.,
2008, Australia [92]
Prospective,
2001–2004,
Australian ICUs
183 62% 17.9% 7.8% 5.6% 3.9% - 0.5% 0.5% - - - 1.8% 2.06 cases/1000
admissions
Chow et al.,
2008, USA [93]
Retrospective,
1995–2005, 2 ICUs
146 54.1% 22.6% 8.2% 8.9% 2.1% - 2.8% - - 1.4% - - NA
Vardakas et al., 2009,
Greece [94]
Retrospective,
2001–2008, 1
medical, surgical ICU
46 67.4% 4.3% 4.3% 10.9% 2.2% 4.3% - 6.5% - - - - 0.6 cases/1000
patient-days
Ref., reference; ICU, intensive care unit; PICU, pediatric intensive care unit; NICU, neonatal intensive care unit; NNISS, National Nosocomial Infection Surveillance System; NA, relevant data were not available.
a Refers to the total number of Candida isolates from blood (or to the total number of candidemia episodes where the former was not available from the original study).
b Includes Candida spp not depicted in the Table and Candida spp not identiﬁed to species level.
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M.E. Falagas et al. / International Journal of Infectious Diseases 14 (2010) e954–e966 e963(8.5% and 10.6%, respectively). Other Candida sppwere isolated in 2–
9% of cases.
Hospital-based studies
C. albicanswas the dominant species inNorth and Central Europe
and the USA. Non-albicans species predominated in South America,
South Europe, and Asia. The highest proportion of C. albicans was
reported in one study conducted in Hungary (81.7%), followed by
studies from Northern Europe (63.5–66.8%), Taiwan (63.7%), and
Switzerland (61.3%). The lowest ﬁgures were observed in Asian
countries (17% and 19%). C. glabrata was more prevalent in studies
fromEurope, reaching proportions of 19.6% to 27%. Zero proportions
were reported in a study from India and low proportions were also
reported in studies from the USA (2.2%), Hungary (2.5%), and Saudi
Arabia (3%). The frequency of C. parapsilosis was highest in Saudi
Arabia (44%), Italy (35.5%), and Portugal (32%), followed by most
studies of American origin (eight out of 10 report proportions of 23–
36%). The lower rateswere reported inSwitzerlandandBrazil (4% for
both studies). C. tropicalis was higher in Asia (33–60%) and South
America (13.3–17%, average 15.5%) and lower inNorth (2–8.5%) and
Central Europe (3.3–7%). As in the surveillance studies, the
proportion of C. krusei was low (1–6%) in all regions. Rates for
other Candida spp ranged from 0.2% to 13.2%.
ICUs
In general very few studies were available and the majority of
them were performed in neonatal and pediatric ICUs. In these
studies C. albicans predominated in Hungary (88.3%), Greece (64.3–
67.4%), Australia (62%), Belgium (59.8%), and the USA (54.3–57.9%
in pediatric ICUs). On the other hand, non-albicans was higher in
India (96%) and South Europe (77%). The relative frequency of C.
glabratawas highest in Ireland (24.2%) and lowest in neonatal ICUs
in the USA (2%). C. parapsilosiswas higher in Spain (67%), followed
by Slovakia (48%) and the USA (33.7%), and was lower in Greece
(4.3%) and Hungary (3.3%). C. tropicalis was most commonly
isolated in India (92%), but its proportion was low in Ireland (6.1%)
and the USA (3.8%). Finally C. krusei was similarly low (up to 3.5%)
in all regions with the exception of one study from Turkey (8.7%).
Prospective and retrospective studies
Twelve out of 21 surveillance andmulticenter studies identiﬁed
C. albicans as the dominant pathogen in patients with candidemia;
all were performed in Europe and the USA. Three studies showed
that C. albicans and non-albicans spp are equally isolated from
blood samples (meaning that the proportion of C. albicans was in
the range of 45–55%) and six more that non-albicans spp are the
most frequently isolated pathogens, all in South America and Asia.
On the other hand, prospective hospital-based studies showed that
non-albicans spp predominated (10 out of 15); all these studies
were performed in South America, Asia, and Europe. Only two
studies, one performed in Sweden and another in Israel, showed
that C. albicans was the dominant species.
Retrospective studies summarizing data from hospitals showed
that C. albicans dominated over non-albicans spp (13 out of 25).
Four studies reported that C. albicans and non-albicans spp were
equally isolated from blood (C. albicans in the range of 48–52%) and
eight more reported that non-albicans spp predominated. Very few
retrospective ICU studies (n = 4) have been published and the
reported outcomes are contradictory, with two showing predomi-
nance of C. albicans and two of non-albicans.
Distribution according to age
Data regarding the relative frequency of Candida spp according
to age are limited (17 studies provided data). Again, differenceswere noted according to study design. Surveillance studies showed
that C. albicans is the major pathogen in all populations (neonates,
pediatrics, and adults). However, ICU- and hospital-based studies
reported variable distributions. Studies performed in neonates
showed that non-albicans species, mainly C. parapsilosis, predomi-
nate (in three out of four). Conclusions could not be drawn from
results in children and adults, since studies favoring both C.
albicans and non-albicans species have been published.
Changes over time
Data regarding changes in the relative frequency of the Candida
spp over time in the individual studies were available only for 12
surveillance studies. An increasing relative frequency of C. glabrata
was reported in ﬁve studies,23,25,27,31,39 all conducted in Central
and North Europe and the USA. In two of them, an increase in the
relative frequency of C. glabrata was noticed with increasing
age.25,39 A decrease in C. glabrata was reported in one study
conducted in the USA.2 The same study reported an increase in the
relative frequency of C. albicans and C. parapsilosis, and a decrease
in C. tropicalis. An increase in C. kruseiwas reported in one study,31
while an overall increase in non-albicans species was reported in
two studies conducted in Belgium and Japan.37,38 In the Japanese
study, the relative frequency of non-albicans species increased
with increasing age. No shift towards non-albicans species was
reported in four studies, all conducted in Europe.22,30,35,36
Discussion
The main ﬁnding of this review is that the epidemiology of
candidemia is considerably different in the various parts of the
world, but it appears that it follows speciﬁc patterns. In general, C.
albicans is the predominately isolated pathogen in North and
Central Europe and the USA. On the other hand, non-albicans
species predominate in Asia, South Europe, and South America. No
data have been published for Africa. The highest proportion of C.
albicanswas reported in North and Central Europe, followed by the
USA, South Europe, and South America, while the lowest frequency
was reported in Asia.
The highest proportions of C. glabrata were reported in North
and Central Europe. In the USA its proportion varied depending on
the setting and/or study design and in Asia depending on the
setting and the speciﬁc geographical region. The lowest proportion
was reported in South Europe. For C. parapsilosis the highest
proportionwas reported in a very small study in Slovakia, followed
by South Europe and South America and Asia. Again, the reported
data from the USA varied depending on setting and/or study
design. The highest proportions of C. tropicalis were found in
Eastern Asia and Argentina, but in general its proportion varied
depending on setting, study design, and geographical region. The
proportion of C. krusei was generally low in all settings and
geographic regions. Data on other Candida spp were not reported
regularly.
Data regarding changes in the relative frequency of Candida spp
isolated from blood were available from 12 surveillance and
multicenter studies. An increase in the frequency of C. glabratawas
reported in ﬁve studies, all conducted in Europe and the USA. Four
additional studies conducted in Europe reported no shift towards
non-albicans species. Data regarding changes over time were not
available from other parts of the world.
Geographic variation may mirror clinical practice in different
parts of the globe. For example, the higher incidence of C. glabrata
in studies in the USA and parts of Europe may be a result of the
extensive use of ﬂuconazole both for prophylaxis and treatment
during the past years, especially in patients with hematological
malignancies. However, this should not be considered as the single
M.E. Falagas et al. / International Journal of Infectious Diseases 14 (2010) e954–e966e964reason since this should have led to a higher incidence of C. krusei
infections as well. Moreover, C. glabrata bloodstream infections
have also been associated with increasing patient age, underlying
disease (mainly cancer), geographic variation, use of speciﬁc
antibiotics (piperacillin–tazobactam and vancomycin), use of
central venous catheters, administration of total parenteral
nutrition, and the isolation system used for species identiﬁcation.
C. parapsilosis has been associated with nosocomial outbreaks
underlying a break in infection control programs, formation of
bioﬁlms in central catheters and other implanted devices, and the
use of parenteral nutrition. C. tropicalis and C. krusei have mainly
been associated with hematological malignancies and neutrope-
nia. C. krusei has also been associated with the use of piperacillin–
tazobactam and vancomycin.94
On the other hand, this may just represent a different species
distribution around the globe, as seen for several – and not only –
microorganisms. Commercially available methods for species
identiﬁcation have become increasingly available over time. In
addition, we should underline the possibility of an increasing
number of species previously considered non-pathogenic that
have emerged as true opportunistic pathogens in immunocom-
promised individuals.94
The study design may play an additional important role. It is
suggested that surveillance studies provide the most representa-
tive and comprehensive data. These studies showed that C. albicans
is still the predominant pathogen of candidemia in general, but
local epidemiology may be strikingly different. Countries in South
Europe may be the best example in this case. We found that
although European surveillance studies reported that C. albicans is
isolated in over 50% of candidemia cases, non-albicans species
were more frequently isolated in single centre studies performed
in South European countries. This ﬁnding emphasizes the
signiﬁcance of local epidemiological data. Finally, although C.
parapsilosis was found to be an important pathogen in neonatal
ICUs, no other possible relationship was found between age and
Candida spp.
These ﬁndings may have potential implications for the
treatment of choice in patients with suspected candidemia.
Therefore, in regions with a high incidence of C. glabrata,
ﬂuconazole should probably not be considered as a ﬁrst-line
treatment. Further, in neonatal ICUs, where a signiﬁcant propor-
tion of candidemia is due to C. parapsilosis, empirical treatment
with echinocandins may be withheld following data showing
decreased susceptibility of this pathogen to echinocandins,
especially caspofungin.95 However, it should be noted that the
clinical signiﬁcance of this ﬁnding has not yet been determined.
Again, physicians should be aware of the local epidemiological
patterns.
The considerable number of retrospective studies included in
this review is among itsmost important limitations. Therefore, it is
not possible to guarantee that they have included all episodes of
candidemia from the period analyzed. In addition, 33 studies had a
population of episodes smaller than 100. This ﬁgure is mainly
found in the studies performed in ICUs (13/18 studies), followed by
hospital-based studies (17/41 of hospital cohorts); hence the
distribution in percentage of the different Candida spp could have
limited validity. In the reported ICU series, there was a predomi-
nance of children and neonates. Therefore, extrapolation of the
results to adult patients admitted to the ICU should be done with
caution.
In conclusion, signiﬁcant variation is evident among cases of
candidemia in different geographic regions, even within the same
continent and probably the same country. C. albicans remains the
main species isolated from blood, but increasing incidence of other
Candida spp has also been reported. Local epidemiological data
continue to be of major signiﬁcance.Conﬂict of interest: No conﬂict of interest to declare.
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